CA2340475A1 - Recepteur orphelin - Google Patents

Recepteur orphelin Download PDF

Info

Publication number
CA2340475A1
CA2340475A1 CA002340475A CA2340475A CA2340475A1 CA 2340475 A1 CA2340475 A1 CA 2340475A1 CA 002340475 A CA002340475 A CA 002340475A CA 2340475 A CA2340475 A CA 2340475A CA 2340475 A1 CA2340475 A1 CA 2340475A1
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
receptor
relates
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002340475A
Other languages
English (en)
Other versions
CA2340475C (fr
Inventor
George G.J.M. Kuiper
Eva Enmark
Jan Ake Gustafsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karo Pharma AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9518272.1A external-priority patent/GB9518272D0/en
Priority claimed from GBGB9605550.4A external-priority patent/GB9605550D0/en
Priority claimed from GBGB9607532.0A external-priority patent/GB9607532D0/en
Priority claimed from GBGB9609576.5A external-priority patent/GB9609576D0/en
Application filed by Individual filed Critical Individual
Priority claimed from CA002201098A external-priority patent/CA2201098C/fr
Publication of CA2340475A1 publication Critical patent/CA2340475A1/fr
Application granted granted Critical
Publication of CA2340475C publication Critical patent/CA2340475C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002340475A 1995-09-08 1996-09-09 Recepteur orphelin Expired - Fee Related CA2340475C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB9518272.1A GB9518272D0 (en) 1995-09-08 1995-09-08 Orphan receptor
GBGB9605550.4A GB9605550D0 (en) 1996-03-15 1996-03-15 Orphan receptor
GBGB9607532.0A GB9607532D0 (en) 1996-04-11 1996-04-11 Orphan receptor
GBGB9609576.5A GB9609576D0 (en) 1996-05-08 1996-05-08 Orphan receptor
GB9518272.1 1996-05-08
GB9609576.5 1996-05-08
GB9605550.4 1996-05-08
GB9607532.0 1996-05-08
CA002201098A CA2201098C (fr) 1995-09-08 1996-09-09 Recepteur orphelin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002201098A Division CA2201098C (fr) 1995-09-08 1996-09-09 Recepteur orphelin

Publications (2)

Publication Number Publication Date
CA2340475A1 true CA2340475A1 (fr) 1997-03-13
CA2340475C CA2340475C (fr) 2002-08-20

Family

ID=27508619

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002340475A Expired - Fee Related CA2340475C (fr) 1995-09-08 1996-09-09 Recepteur orphelin

Country Status (1)

Country Link
CA (1) CA2340475C (fr)

Also Published As

Publication number Publication date
CA2340475C (fr) 2002-08-20

Similar Documents

Publication Publication Date Title
CA2201098A1 (fr) Recepteur orphelin
AU1378499A (en) Methods for treating prostate tumors using radioactive compositions
AU6045398A (en) Androgen synthesis inhibitors
MXPA00012586A (es) Glicosulfopeptidos y metodos de sintesis y uso de los mismos.
EP1310509A3 (fr) Nouveaux stéroides anti-oestrogènes, compositions pharmaceutiques associées et leur mode d'utilisation
WO1997044063A3 (fr) Conjugues d'acide cis-docosahexanoïque et d'agents pharmaceutiques
BR9710636A (pt) Análogo de somatostatina ciclizada da espinha dorsal, uso do mesmo, composição farmacêutica,e , processo de tratamento de distúrbios endócrinos, neoplasmas ou distúrbios metabólicos.
AU8693098A (en) Compositions and methods for treating diabetes
BG103436A (en) Conjugates applicable in the treatment of the prostate gland cancer
IL128331A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
EP1009755A4 (fr) Inhibiteurs de steroide sulfatase et leurs methodes de production et d'utilisation
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
WO1997029199A3 (fr) Peptides pour l'antigene prostatique specifique et leurs utilisations
AU6633694A (en) Novel methods and compositions for the treatment of (ras)-activated cancer with heterotypic anti-(raf) antisense oligonucleotides
CA2288650A1 (fr) Procede de traitement de maladie mentale chez les mammiferes et composition a cet effet
CA2340475A1 (fr) Recepteur orphelin
ZA986520B (en) Coating composition and process for its preparation
Miller et al. Elevated intrinsic reactivity of seryl hydroxyl groups within the linear peptide triads His-Xaa-Ser or Ser-Xaa-His
EP1512755A3 (fr) Marqueurs moléculaires du cancer de la prostate
AU1719500A (en) Method for augmenting the inotropic effects of beta-adrenergic agonists using pyruvate therapy
AU1114499A (en) A composition for the treatment of legionella pneumophila and a method for such treatment
EP1077892A4 (fr) Procede et composition permettant d'ameliorer l'uniformite d'application d'un ensimage
AU2390700A (en) Polypeptidic compositions and methods for the treatment of tumors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140909